Detalles de la búsqueda
1.
Intratumoral delivery of TransCon™ TLR7/8 Agonist promotes sustained anti-tumor activity and local immune cell activation while minimizing systemic cytokine induction.
Cancer Cell Int
; 22(1): 286, 2022 Sep 19.
Artículo
en Inglés
| MEDLINE | ID: mdl-36123697
2.
TransCon CNP, a Sustained-Release C-Type Natriuretic Peptide Prodrug, a Potentially Safe and Efficacious New Therapeutic Modality for the Treatment of Comorbidities Associated with Fibroblast Growth Factor Receptor 3-Related Skeletal Dysplasias.
J Pharmacol Exp Ther
; 370(3): 459-471, 2019 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-31235532
3.
TransCon IL-2 ß/γ: a novel long-acting prodrug with sustained release of an IL-2Rß/γ-selective IL-2 variant with improved pharmacokinetics and potent activation of cytotoxic immune cells for the treatment of cancer.
J Immunother Cancer
; 10(7)2022 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-35817480
4.
Design and Preclinical Development of TransCon PTH, an Investigational Sustained-Release PTH Replacement Therapy for Hypoparathyroidism.
J Bone Miner Res
; 34(11): 2075-2086, 2019 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-31291476
Resultados
1 -
4
de 4
1
Próxima >
>>